Stent coated by a compound

ABSTRACT

A stent coated by a compound represented by the general formula (1) below which is produced by reaction between rapamycin and alkyl triflate in an organic solvent which is a chlorine-containing organic solvent, wherein said reaction is carried out in the presence of trialkylamine,  
                 
where R denotes alkyl, arylalkyl, hydroxyalkyl, alkoxyalkyl, acyloxyalkyl, aminoalkyl, alkylaminoalkyl, alkoxycarbonylaminoalkyl, acylaminoalkyl, or aryl.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional of application Ser. No. 11,067,718,filed Mar. 1, 2005, the contents of which are incorporated herein byreference, which claims priority to Japanese Application No.2004-056233, filed Mar. 1, 2004.

BACKGROUND OF THE INVENTION

The present invention relates to a process for producingO-alkylrapamycin derivatives by reaction between rapamycin and alkyltriflate.

Rapamycin is one of macrolide antibiotics produced by Streptomyceshygroscopicus. It exhibits immunosuppresive actions, carcinostaticactions, and antifungal actions. Because of such useful pharmaceuticalactivity, much has been reported about rapamycin derivatives (See Drugsof Future, 1999, 24(1): 22-29).

On the other hand, synthesis of rapamycin derivatives has been reportedby Cottens et al (See WO94/09010 official gazette). This documentdiscloses a process for producing an O-alkylrapamycin derivative byreaction between rapamycin and alkyl triflate in the presence oflutidine in toluene (as a solvent). However, it mentions nothing aboutthe yield that is attained by the disclosed process. Furtherinvestigation by the present inventors revealed that the yield is only23% (refer to Comparative Example 1 mentioned later), which suggeststhat O-alkylating reaction does not proceed smoothly as desired.Therefore, a great improvement in the process of synthesis has beenrequired for effective use of very expensive rapamycin.

SUMMARY OF THE INVENTION

It is an object of the present invention to provide a process forefficient production of an O-alkylrapamycin derivative. This process -isdesigned to improve yields in the step of O-alkylating. The presentinvention is based on the idea that increasing the reactivity is a keyto the synthesis of rapamycin derivatives mentioned above.

In order to tackle the problem, the present inventors carried outextensive studies, which led to the finding that it is possible toefficiently produce O-alkylrapamycin derivatives in greatly improvedyields if the reaction between rapamycin and alkyl triflate isaccomplished in the presence of trialkylamine in an organic solvent. Thepresent invention is based on this finding.

The present invention is directed to a process for efficient productionof an O-alkylrapamycin derivative, the process being defined in thefollowing paragraphs (1) to (14).

-   (1) A process for production of an O-alkylrapamycin derivative    represented by the general formula (1) below by reaction between    rapamycin and alkyl triflate in an organic solvent, characterized in    that the reaction is carried out in the presence of trialkylamine,    where R denotes alkyl, arylalkyl, hydroxyalkyl, alkoxyalkyl,    acyloxyalkyl, aminoalkyl, alkylaminoalkyl, alkoxycarbonylaminoalkyl,    acylaminoalkyl, or aryl.-   (2) The process for production of an O-alkylrapamycin derivative as    defined in (1), wherein the trialkylamine is used in an amount not    less than 30 mol per mol of rapamycin.-   (3) The process for production of an O-alkylrapamycin derivative as    defined in (1) or (2), wherein the trialkylamine is    N,N-diisopropylethylamine.-   (4) The process for production of an O-alkylrapamycin derivative as    defined in any of (1) to (3), wherein the organic solvent is a    chlorine-containing organic solvent.-   (5) The process for production of an O-alkylrapamycin derivative as    defined in (4), wherein the chlorine-containing organic solvent is    methylene chloride or chloroform.-   (6) The process for production of an O-alkylrapamycin derivative as    defined in any of (1) to (5), wherein the organic solvent is used in    an amount of 2 to 6 parts by weight for 1 part by weight of    rapamycin.-   (7) The process for production of an O-alkylrapamycin derivative as    defined in any of (1) to (6), wherein the alkyl triflate is used in    an amount of 5 to 20 mol per mol of the O-alkylrapamycin derivative.-   (8) The process for production of an O-alkylrapamycin derivative as    defined in any of (1) to (7), wherein the alkyl triflate is    2-ethoxyethyl triflate.-   (9) The process for production of an O-alkylrapamycin derivative as    defined in any of (1) to (8), wherein the process includes an    additional step for purification in which the O-alkylrapamycin    derivative synthesized by the process defined in any of (1) to (8)    is placed in a mixed solvent composed of water and at least one    water-miscible solvent or placed in water or a water-containing    mixed solvent after dissolution in at least one water-miscible    solvent, and subsequently allowed to precipitate out.-   (10) The process for production of an O-alkylrapamycin derivative as    defined in (9), wherein the water-miscible solvent is used in an    amount of 2 to 10 parts by weight for 1 part by weight of the    O-alkylrapamycin derivative.-   (11) The process for production of an O-alkylrapamycin derivative as    defined in (9) or (16), wherein the water is used in an amount not    less than 10 parts by weight for 1 part by weight of the    O-alkylrapamycin derivative.-   (12) The process for production of an O-alkylrapamycin derivative as    defined in any of (9) to (11), wherein the water-miscible solvent is    an alcohol.-   (13) The process for production of an O-alkylrapamycin derivative as    defined in (12), wherein the alcohol is methanol.-   (14) The process for production of an O-alkylrapamycin derivative as    defined in any of (9) to (13), wherein the step of precipitation is    carried out such that the O-alkylrapamycin derivative is dissolved    in a solvent containing at least one water-miscible solvent and    subsequently the resulting solution is placed in water or a mixed    solvent composed of water and at least one water-miscible solvent.

With the above-mentioned production process according to the presentinvention, it is possible to improve yields in reaction for O-alkylationand to efficiently produce an O-alkylrapamycin derivative.

BRIEF DESCRIPTION OF THE DRAWING

FIG. 1 is an NMR chart which proves that the compound synthesized by theprocess according to the present invention isO-(2-ethoxyethyl)-rapamycin.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention will be described in more detail in the following.

The present invention covers a process for production of anO-alkylrapamycin derivative represented by the general formula (1) belowby reaction between rapamycin and alkyl triflate in an organic solvent,characterized in that the reaction is carried out in the presence oftrialkylamine.

(where R denotes alkyl, arylalkyl, hydroxyalkyl, alkoxyalkyl,acyloxyalkyl, aminoalkyl, alkylaminoalkyl, alkoxycarbonylaminoalkyl,acylaminoalkyl, or aryl.)

An example of the O-alkylrapamycin derivative (with R=alkoxyalkyl)represented by the general formula 1 above isO-(2-ethoxyethyl)-rapamycin represented by the general formula 2 below.

The O-(2-ethoxyethyl)-rapamycin can be produced by reaction betweenrapamycin and 2-ethoxyethyl triflate in the presence ofN,N-diisopropylethylamine in methylene chloride.

An example of the O-alkylrapamycin derivative (with R=hydroxyalkyl) isO-(2-hydroxyethyl)-rapamycin represented by the general formula 3 below.

The O-(2-hydroxyethyl)-rapamycin can be produced by reaction betweenrapamycin and t-butyldimethylsilyloxyethyl triflate in the presence ofN,N-diisopropylethylamine in methylene chloride, followed bydeprotecting of t-butyldimethylsilyl group.

The following are the examples of the trialkylamine which is used insynthesis of O-alkylrapamycin derivatives by the process according tothe present invention: trimethylamine; triethylamine; tri-n-propylamine;triisopropylamine; tri-n-butylamine; tri(2-methyl-n-propyl)amine;tri(3-methyl-n-propyl)amine; N,N-dimethylethylamine;N,N-diethylmethylamine; N,N-di-n-propylmethylamine;N,N-diisopropylmethylamine; N,N-di-n-butylmethylamine;N,N-di(2-methyl-n-propyl)methylamine;N,N-di(3-methyl-n-propyl)methylamine; N,N-di-n-propylethyalmine,N,N-diisopropylethylamine, N,N-di-n-butylethylamine,N,N-di(2-methyl-n-propyl)ethylamine; andN,N-di(3-methyl-n-propyl)ethylamine. Particularly desirable of theseexamples are triethylamine, N,N-di-n-propylethyalmine,N,N-diisopropylethylamine, N,N-di-n-butylethylamine,N,N-di(2-methyl-n-propyl)ethylamine, andN,N-di(3-methyl-n-propyl)ethylamine. Most desirable isN,N-diisopropylethylamine.

In the synthesis of O-alkylrapamycin derivatives by the processaccording to the present invention, the trialkylamine should be used inan amount not less than 5 mol, preferably not less than 10 mol, morepreferably not less than 30 mol, per mol of rapamycin.

In the synthesis of O-alkylrapamycin derivatives by the processaccording to the present invention, the organic solvent is notspecifically restricted so long as it dissolves the starting materialsand the reaction products. It should preferably be a halogen-containingorganic solvent, more preferably a chlorine-containing organic solvent,typically methylene chloride and chloroform.

In the synthesis of O-alkylrapamycin derivatives by the processaccording to the present invention, the organic solvent should be usedin an amount not less than 1 part by weight, preferably 2 to 6 parts byweight, for 1 part by weight of rapamycin.

In the synthesis of O-alkylrapamycin derivatives by the processaccording to the present invention, the alkyl triflate should be used inan amount not less than 1 mol, preferably 5 to 20 mol, per mol ofrapamycin.

The O-alkylrapamycin derivative synthesized by the process according tothe present invention may be purified by dissolving the O-alkylrapamycinderivative in a water-miscible solvent such as alcohol and then placingthe resulting solution in water for precipitation. Purification may alsobe accomplished by dissolving the O-alkylrapamycin derivative in a mixedsolvent composed of water and at least one water-miscible solvent andallowing the resulting solution to stand for precipitation.

The purified O-alkylrapamycin derivative is powder. The powder has theadvantage of improving the handling when coating to stent, the qualitystability and the preservation stability.

The solvent used for purification of the O-alkylrapamycin synthesized bythe process according to the present invention is not specificallyrestricted so long as it is miscible with water. It should preferably bean alcohol, particularly methanol.

For purification of the O-alkylrapamycin derivatives synthesized by theprocess according to the present invention, the solvent should be usedin an amount not less than 3 parts by weight, preferably not less than10 parts by weight, for 1 part by weight of O-rapamycin.

One use of the O-alkylrapamycin derivative synthesized by the process ofthe present invention is coating on a medical equipment, such as stent.The coated stent is indwelled in a lesion such as blood vessel, so thatthe O-alkylrapamycin derivative is uptaken into the lesion to preventrestenosis.

EXAMPLES

The invention will be described with reference to the followingexamples, which demonstrate the efficient production of O-alkylrapamycinderivatives by the process of the present invention.

Example 1 (1) Synthesis of 2-ethoxyethyl triflate

In a round bottom flask containing a stirring bar was placed 9.0 g (100mmol) of ethoxyethanol. The atmosphere in the flask was replaced withnitrogen by using a nitrogen bubbler. The flask was given 160 mL ofmethylene chloride and 23.3 mL (120 mmol) of 2,6-lutidine. The flaskcooled with ice was given dropwise 20.2 mL (120 mmol) oftrifluoromethanesulfonic acid anhydride over 20 minutes. After stirringfor 1 hour, the reaction liquid was mixed with 20 mL of saturatedsolution of ammonium chloride. The resulting mixture was washedsequentially with 1N hydrochloric acid (100 mL), deionized water (100mL), saturated solution of sodium hydrogen carbonate (100 mL), andsaturated aqueous solution of sodium chloride (100 mL). The organiclayer was separated and dried with anhydrous sodium sulfate. With thesodium sulfate filtered off, the solution was concentrated under reducedpressure. The residue underwent silica gel chromatography. Thus therewas obtained 15.03 g (67.6% yields) of 2-ethoxyethyl triflate from thefraction in eluate of 20% ethyl acetate-hexane.

(2) Synthesis of 40-O-[(2′-ethoxy)ethyl]rapamycin

In a round bottom flask containing a stirring bar was placed 1.0 g (1.09mmol) of rapamycin. With the flask connected to a condenser, theatmosphere in the flask was replaced with nitrogen by using a nitrogenbubbler. To the flask was added 3.5 mL of methylene chloride fordissolution. To the flask was further added 10 mL (57.5 mmol) ofN,N-diisopropylethylamine and 1.95 g (8.78 mmol) of the previouslysynthesized 2-ethoxyethyl triflate with vigorous stirring. With theflask kept at 60° C. in an oil bath, the content was stirred for 1 hourand 20 minutes. The resulting mixture was diluted with 100 mL of ethylacetate and washed sequentially with 100 mL of 1N hydrochloric acid, 100mL of deionized water, and 80 mL of saturated aqueous solution of sodiumchloride. The ethyl acetate phase was separated and then stirred with 5g of anhydrous sodium sulfate for 20 minutes. With the sodium sulfatefiltered off, the solution was concentrated by using a rotaryevaporator. The concentrated solution was purified using a columnchromatograph, with a silica gel bed measuring 4 cm in diameter and 26cm high. Elution was accomplished by flowing sequentially 300 mL ofethyl acetate/n-hexane (1:1 v/v), 1000 mL of ethyl acetate/n-hexane(3:2, v/v), and 300 mL of ethyl acetate/n-hexane (7:3, v/v). The desiredfraction was collected and concentrated, and the concentrate was vacuumdried in a desiccator. Thus there was obtained 494 mg (0.501 mmol) ofthe desired product (46% yields).

Example 2

In a round bottom flask containing a stirring bar was placed 1.0 g (1.09mmol) of rapamycin. With the flask connected to a condenser, theatmosphere in the flask was replaced with nitrogen by using a nitrogenbubbler. To the flask was added 3.5 mL of chloroform for dissolution. Tothe flask was further added 10 mL (57.5 mmol) ofN,N-diisopropylethylamine and 1.95 g (8.78 mmol) of the 2-ethoxyethyltriflate previously synthesized in Example 1 with vigorous stirring.With the flask kept at 60° C. in an oil bath, the content was stirredfor 1 hour and 20 minutes. The resulting mixture was diluted with 100 mLof ethyl acetate and washed sequentially with 100 mL of 1N hydrochloricacid, 100 mL of deionized water, and 80 mL of saturated aqueous solutionof sodium chloride. The ethyl acetate phase was separated and thenstirred with 5 g of anhydrous sodium sulfate for 20 minutes. With thesodium sulfate filtered off, the solution was concentrated using arotary evaporator. The concentrated solution was purified using columnchromatograph, with a silica gel bed measuring 4 cm in diameter and 26cm high. Elution was accomplished by flowing sequentially 300 mL ofethyl acetate/n-hexane (1:1, v/v), 1000 mL of ethyl acetate/n-hexane(3:2, v/v), and 300 mL of ethyl acetate/n-hexane (7:3, v/v). The desiredfraction was collected and concentrated, and the concentrate was vacuumdried in a desiccator. Thus there was obtained 451 mg (0.458 mmol) ofthe desired product (42% yields).

Example 3

In a round bottom flask containing a stirring bar was placed 1.0 g (1.09mmol) of rapamycin. With the flask connected to a condenser, theatmosphere in the flask was replaced with nitrogen by using a nitrogenbubbler. To the flask was. added 3.5 mL of methylene chloride fordissolution. To the flask was further added 8 mL (57.4 mmol) oftriethylamine and 1.95 g (8.78 mmol) of the 2-ethoxyethyl triflatepreviously synthesized in Example 1 with vigorous stirring. With theflask kept at 60° C. in an oil bath, the content was stirred for 1 hourand 20 minutes. The resulting mixture was diluted with 100 mL of ethylacetate and washed sequentially with 100 mL of 1N hydrochloric acid, 100mL of deionized water, and 80 mL of saturated aqueous solution of sodiumchloride. The ethyl acetate phase was separated and then stirred with 5g of anhydrous sodium sulfate for 20 minutes. With the sodium sulfatefiltered off, the solution was concentrated using a rotary evaporator.The concentrated solution was purified using column chromatograph, witha silica gel bed measuring 4 cm in diameter and 26 cm high. Elution wasaccomplished by flowing sequentially 300 mL of ethyl acetate/n-hexane(1:1, v/v), 1000 mL of ethyl acetate/n-hexane (3:2, v/v), and 300 mL ofethyl acetate/n-hexane (7:3, v/v) . The desired fraction was collectedand concentrated, and the concentrate was vacuum dried in a desiccator.Thus there was obtained 344 mg (0.349 mmol) of the desired product (32%yields).

Example 4

In 2 mL of methanol was dissolved 500 mg of the40-O-[(2′-ethoxy)ethyl]rapamycin which had been obtained in Example 1.The resulting solution was added dropwise to 20 mL of deionized waterwith stirring. The solids which had precipitated out were filtered offand washed with a small amount of water and finally dried under reducedpressure at 40° C. for more than 10 hours. Thus there was obtained 483mg of white powder.

This product gave an NMR chart as shown in FIG. 1. This NMR chartindicates the structure of 40-O-[(2′-ethoxy)ethyl]rapamycin representedby the general formula 4.

Comparative Example

A sample of 40-O-[(2′-ethoxy)ethyl]rapamycin was synthesized by theprocess disclosed in WO94/09010 official gazette so as to evaluateyields.

In a round bottom flask containing a stirring bar was placed 1.0 g (1.09mmol) of rapamycin. With the flask connected to a condenser, theatmosphere in the flask was replaced with nitrogen by using a nitrogenbubbler. To the flask was added 3.5 mL of toluene for dissolution. Tothe flask was further added 467 mg (4.36 mmol) of 2,6-lutidine and 1.95g (8.78 mmol) of the 2-ethoxyethyl triflate previously synthesized inExample 1 with vigorous stirring. With the flask kept at 60° C. in anoil bath, the content was stirred for 1 hour and 20 minutes. Theresulting mixture was diluted with 100 mL of ethyl acetate and washedsequentially with 100 mL of 1N hydrochloric acid, 100 mL of deionizedwater, and 80 mL of saturated aqueous solution of sodium chloride. Theethyl acetate phase was separated and then stirred with 5 g of anhydroussodium sulfate for 20 minutes. With the sodium sulfate filtered off, thesolution was concentrated using a rotary evaporator. The concentratedsolution was purified using column chromatograph, with a silica gel bedmeasuring 4 cm in diameter and 26 cm high. Elution was accomplished byflowing sequentially 300 mL of ethyl acetate/n-hexane (1:1, v/v), 1000mL of ethyl acetate/n-hexane (3:2, v/v), and 300 mL of ethylacetate/n-hexane (7:3, v/v). The desired fraction was collected andconcentrated, and the concentrate was vacuum dried in a desiccator. Thusthere was obtained 247 mg (0.251 mmol) of the desired product (23%yields).

1. A stent coated by a compound represented by the general formula (1)below which is produced by reaction between rapamycin and alkyl triflatein an organic solvent which is a chlorine-containing organic solvent,wherein said reaction is carried out in the presence of trialkylamine,

where R denotes alkyl, arylalkyl, hydroxyalkyl, alkoxyalkyl,acyloxyalkyl, aminoalkyl, alkylaminoalkyl, alkoxycarbonylaminoalkyl,acylaminoalkyl, or aryl.
 2. The stent as defined in claim 1, wherein thetrialkylamine is used in an amount not less than 30 mol per mol ofrapamycin.
 3. The stent as defined in claim 1, wherein the trialkylamineis N,N-diisopropylethylamine.
 4. The stent as defined in claim 1,wherein the chlorine-containing organic solvent is methylene chloride orchloroform.
 5. The stent as defined in claim 1, wherein the organicsolvent is used in an amount of 2 to 6 parts by weight for 1 part byweight of rapamycin.
 6. The stent as defined in claim 1, wherein thealkyl triflate is used in an amount of 5 to 20 mol per mol of thecompound represented by formula (1).
 7. The stent as defined in claim 1,wherein the alkyl triflate is 2-ethoxyethyl triflate.
 8. The stent asdefined in claim 1, wherein the compound is produced by an additionalstep for purification in which the compound represented by formula (1)is placed in a mixed solvent comprising water and at least onewater-miscible solvent or placed in water or a water-containing mixedsolvent after dissolution in at least one water-miscible solvent, andsubsequently allowed to precipitate out.
 9. The stent as defined inclaim 8, wherein the water-miscible solvent is used in an amount of 2 to10 parts by weight for 1 part by weight of the compound represented byformula (1).
 10. The stent as defined in claim 8, wherein the water isused in an amount not less than 10 parts by weight for 1 part by weightof the compound represented by formula (1).
 11. The stent as defined inclaim 8, wherein the water-miscible solvent is an alcohol.
 12. The stentas defined in claim 11, wherein the alcohol is methanol.
 13. The stentas defined in claim 8, wherein the step of precipitation is carried outsuch that the compound represented by formula (1) is dissolved in asolvent containing at least one water-miscible solvent and subsequentlythe resulting solution is placed in water or a mixed solvent comprisingwater and at least one water-miscible solvent.